An experimental drug for treating severe asthma from GlaxoSmithKline nearly halved the number of attacks suffered by patients with a hard-to-treat form of the disease in a clinical study, boosting hopes for its commercial success
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment